Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.68

-2.4%

Dec 12 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Ian@SI	3/3/2005 5:47:15 PM
	Read Replies (1) of 52153

$200M seems like an exorbitant price to pay for a 2% reduction in royalties. Wouldn't that same amount invested in CTIC, for example, produce a lot more value than the royalties saved???? re: 16:15 ET Cubist Pharma to purchase 2% reduction in Cubicin royalty rate from LLY (CBST) 10.44 -0.08: Co today announced that it entered into definitive agreements to purchase from Eli Lilly (LLY) a 2% reduction in the royalties payable to Lilly on net sales of Cubicin. Cubist acquired worldwide development and commercialization rights to daptomycin from Lilly in 1997. Upon the closing of the transaction, Cubist will issue to Lilly $20 mln in Cubist common stock with associated registration rights.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next